Literature DB >> 1670946

IL-1 alpha is produced by T lymphocytes activated via the CD2 plus CD28 pathways.

C Cerdan1, Y Martin, H Brailly, M Courcoul, S Flavetta, R Costello, C Mawas, F Birg, D Olive.   

Abstract

In addition to activation via the TCR complex, resting purified T cells can be activated to proliferate by mAb directed against the two surface molecules, CD2 and CD28. We demonstrate here that only the CD2 plus CD28 combined activation induces the expression and secretion of IL-1 alpha, a cytokine classically considered as a monokine. In contrast, neither IL-1 beta nor IL-6 were produced. A second monokine, TNF-alpha was transiently expressed by T cells activated with either CD2 or CD28 mAb, but was expressed to higher levels and with a prolonged kinetics in cells activated by the CD2 plus CD28 combination. The prolonged expression of the IL-1 alpha gene could account, at least in part, for the monocyte-independent and long lasting T cell proliferation induced by the CD2 plus CD28 co-stimulation. Secretion of monokines, such as IL-1 alpha, by activated T cells, could play a regulatory role in immune responses, as well as contribute to autoimmune processes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670946

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Novel CD28-responsive enhancer activated by CREB/ATF and AP-1 families in the human interleukin-2 receptor alpha-chain locus.

Authors:  J H Yeh; P Lecine; J A Nunes; S Spicuglia; P Ferrier; D Olive; J Imbert
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

2.  Potential role of B7-1 and CD28 molecules in immunosuppression in leprosy.

Authors:  J N Agrewala; B Kumar; H Vohra
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

3.  Disparate effects of phorbol esters, CD3 and the costimulatory receptors CD2 and CD28 on RANTES secretion by human T lymphocytes.

Authors:  Y Sotsios; P J Blair; J Westwick; S G Ward
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

4.  Human CD4+ T cells expressing CD45RA acquire the lymphokine gene expression of CD45RO+ T-helper cells after activation in vitro.

Authors:  K Kristensson; C A Borrebaeck; R Carlsson
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

5.  Interleukin-7 is a potent co-stimulus of the adhesion pathway involving CD2 and CD28 molecules.

Authors:  R Costello; H Brailly; F Mallet; C Mawas; D Olive
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

6.  RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter.

Authors:  J H Lai; G Horvath; J Subleski; J Bruder; P Ghosh; T H Tan
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

7.  Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1.

Authors:  G A van Seventer; W Newman; Y Shimizu; T B Nutman; Y Tanaka; K J Horgan; T V Gopal; E Ennis; D O'Sullivan; H Grey
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

8.  In vivo regulation of interleukin-2 receptor alpha gene transcription by the coordinated binding of constitutive and inducible factors in human primary T cells.

Authors:  M Algarté; P Lécine; R Costello; A Plet; D Olive; J Imbert
Journal:  EMBO J       Date:  1995-10-16       Impact factor: 11.598

9.  IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase.

Authors:  M Los; H Schenk; K Hexel; P A Baeuerle; W Dröge; K Schulze-Osthoff
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

10.  Consequences of Vitamin A Deficiency: Immunoglobulin Dysregulation, Squamous Cell Metaplasia, Infectious Disease, and Death.

Authors:  Sherri L Surman; Rhiannon R Penkert; Robert E Sealy; Bart G Jones; Tony N Marion; Peter Vogel; Julia L Hurwitz
Journal:  Int J Mol Sci       Date:  2020-08-04       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.